PnPP‐19, a spider toxin peptide, induces peripheral antinociception through opioid and cannabinoid receptors and inhibition of neutral endopeptidase
- 10 March 2016
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 173 (9) , 1491-1501
Abstract
Background and Purpose: The synthetic peptide PnPP‐19 has been studied as a new drug candidate to treat erectile dysfunction. However, PnTx2–6, the spider toxin from which the peptide was designed, induces hyperalgesia. Therefore, we intended to investigate the role of PnPP‐19 in the nociceptive pathway.Experimental Approach: Nociceptive thresholds were measured by paw pressure test. PnPP‐19 was administered intraplantarly alone or with selective cannabinoid or opioid receptor antagonists. The hydrolysis of PnPP‐19 by neutral endopeptidase (NEP) (EC 3.4.24.11), an enzyme that cleaves enkephalin, was monitored by HPLC and the cleavage sites were deduced by LC–MS. Inhibition by PnPP‐19 and Leu‐enkephalin of NEP enzyme activity was determined spectrofluorimetrically.Key Results: PnPP‐19 (5, 10 and 20 μg per paw) induced peripheral antinociception in rats. Specific antagonists of μ opioid receptors (clocinnamox), δ opioid receptors (naltrindole) and CB1receptors (AM251) partly inhibited the antinociceptive effect of PnPP‐19. Inhibition of fatty acid amide hydrolase by MAFP or of anandamide uptake by VDM11 enhanced PnPP‐19‐induced antinociception. NEP cleaved PnPP‐19 only after a long incubation, andKivalues of 35.6 ± 1.4 and 14.6 ± 0.44 μmol·L−1 were determined for PnPP‐19 and Leu‐enkephalin respectively as inhibitors of NEP activity.Conclusions and Implications: Antinociception induced by PnPP‐19 appears to involve the inhibition of NEP and activation of CB1, μ and δ opioid receptors. Our data provide a greater understanding of the antinociceptive effects of PnPP‐19. This peptide could be useful as a new antinociceptive drug candidate.Keywords
This publication has 64 references indexed in Scilit:
- G Protein-Coupled Receptor Heteromerization: A Role in Allosteric Modulation of Ligand BindingMolecular Pharmacology, 2011
- Animal research: Reporting in vivo experiments: The ARRIVE guidelinesBritish Journal of Pharmacology, 2010
- Central antinociception induced by µ‐opioid receptor agonist morphine, but not δ‐ or κ‐, is mediated by cannabinoid CB1receptorBritish Journal of Pharmacology, 2009
- The opiorphin gene (ProL1) and its homologues function in erectile physiologyBJU International, 2008
- The μ‐opioid receptor agonist morphine, but not agonists at δ‐ or κ‐opioid receptors, induces peripheral antinociception mediated by cannabinoid receptorsBritish Journal of Pharmacology, 2008
- Tx2-6 toxin of the Phoneutria nigriventer spider potentiates rat erectile functionToxicon, 2008
- hSMR3A as a Marker for Patients With Erectile DysfunctionJournal of Urology, 2007
- Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptorsNature Neuroscience, 2007
- Human Opiorphin, a natural antinociceptive modulator of opioid-dependent pathwaysProceedings of the National Academy of Sciences, 2006
- μ opioid and CB1 cannabinoid receptor interactions: reciprocal inhibition of receptor signaling and neuritogenesisBritish Journal of Pharmacology, 2006